Astellas Pharma US, INC.
pharmaceutical company
Based in IL
🤖
AI Overview
With $1.5M in lobbying spend across 27 quarterly filings, Astellas Pharma US, INC. is a significant lobbying presence.
$1.5M
Total Lobbying Spend
27
Quarterly Filings
1
Lobbying Firms Used
3
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $200K |
| 2019 | $250K |
| 2020 | $250K |
| 2021 | $240K |
| 2022 | $240K |
| 2023 | $240K |
| 2024 | $60K |
Lobbying Firms
ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
What They Lobby For
- - Issues related to the Bayh-Dole Act (Pub. L. 96-517) - Issues related to drug pricing and value, generally - Issues related to the importation of prescription medicines, generally
- - Issues related to lobbying disclosure for US affiliates in the Disclosing Foreign Influence Act (H.R.4170/S. 2039) and Foreign Agents Registration Amendments Act (S. 2482)
- - Issues related to Medicare Part B (HOPPS), generally - Issues related to Medicare Part D; the Bipartisan Budget Act (H.R. 1892); and the Consolidated Appropriations Act (H.R. 1625) - Issues related to the repeal of the Independent Payment Advisory Board (IPAB); Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849/S. 260); Protecting Medicare from Executive Action Act of 2017 (S. 251)
- "Issues related to lobbying disclosure for US affiliates in the Disclosing Foreign Influence Act (H.R.4170/S. 2039) and Foreign Agents Registration Amendments Act (S. 2482)"
- Issues related to Medicare Part D
- HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to the Bayh-Dole Act (Pub. L. 96-517) Issues related to drug pricing and value, generally Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) (S. 2852/H.R. 6378) Issues related to the importation of prescription medicines, generally
- HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Issues related to march-in rights under the Bayh-Dole Act (Pub. L. 96-517) Issues related to drug pricing and value, generally Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) Issues related to the importation of prescription medicines, generally
- Issues related to lobbying disclosure for US affiliates
- Issues related to Medicare Part D, generally
- House and Senate Appropriations for FY ending Sept. 30, 2019
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Foreign Governments Are Lobbying Congress
1,000+ foreign entities from 50+ countries lobby the US government.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.